Captor Therapeutics S.A. (CTX)
GPW
Closed
Aug 25, 2026
Day's Range
69.7052 wk Range
33.00Profile - CTX - Captor Therapeutics S.A.
Profile
Mic Code
XWAR
Sector
Healthcare
Industry
Biotechnology
Employees
105
Captor Therapeutics S.A. is an innovative biotechnology company specializing in the development of targeted protein degradation technologies aimed at treating serious medical conditions. Its primary function is to address diseases that do not respond well to traditional small molecule drugs, offering novel therapeutic solutions for unmet medical needs. The company operates in the pharmaceutical and healthcare sectors, focusing on creating protein degrader therapies that either inhibit or activate specific protein targets within cells. This approach allows Captor Therapeutics to intervene in a wide range of diseases, including cancer, neurodegenerative disorders, and autoimmune conditions. Headquartered in Poland, Captor Therapeutics plays a significant role in the biopharmaceutical industry by revolutionizing how complex diseases are treated. By developing drug candidates that exploit the body’s natural protein degradation mechanisms, the company contributes to advancing precision medicine. Captor Therapeutics stands out in the market for its commitment to scientific excellence and its robust pipeline of therapies that have the potential to transform patient care globally.
Profile Details
Type
Common Stock
Ceo
Dr. Thomas Shepherd Ph.D.
Address
Ul. Dunska 11
City
Wroclaw
Zip
54-427
Country
Poland
Phone
48 53 786 9089
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
